Molecular Alterations in Primary Prostate Cancer after Androgen Ablation Therapy

Purpose: After an initial response to androgen ablation, most prostate tumors recur, ultimately progressing to highly aggressive androgen-independent cancer. The molecular mechanisms underlying progression are not well known in part due to the rarity of androgen-independent samples from primary and metastatic sites. Experimental Design: We compared the gene expression profiles of 10 androgen-independent primary prostate tumor biopsies with 10 primary, untreated androgen-dependent tumors. Samples were laser capture microdissected, the RNA was amplified, and gene expression was assessed using Affymetrix Human Genome U133A GeneChip. Differential expression was examined with principal component analysis, hierarchical clustering, and Student's t testing. Analysis of gene ontology was done with Expression Analysis Systematic Explorer and gene expression data were integrated with genomic alterations with Differential Gene Locus Mapping. Results: Unsupervised principal component analysis showed that the androgen-dependent and androgen-independent tumors segregated from one another. After filtering the data, 239 differentially expressed genes were identified. Two main gene ontologies were found discordant between androgen-independent and androgen-dependent tumors: macromolecule biosynthesis was down-regulated and cell adhesion was up-regulated in androgen-independent tumors. Other differentially expressed genes were related to interleukin-6 signaling as well as angiogenesis, cell adhesion, apoptosis, oxidative stress, and hormone response. The Differential Gene Locus Mapping analysis identified nine regions of potential chromosomal deletion in the androgen-independent tumors, including 1p36, 3p21, 6p21, 8p21, 11p15, 11q12, 12q23, 16q12, and 16q21. Conclusions: Taken together, these data identify several unique characteristics of androgen-independent prostate cancer that may hold potential for the development of targeted therapeutic intervention.

[1]  E. Petricoin,et al.  Laser Capture Microdissection , 1996, Science.

[2]  Yu Shyr,et al.  Coupled analysis of gene expression and chromosomal location. , 2005, Genomics.

[3]  N. Gerry,et al.  Reliability and reproducibility of gene expression measurements using amplified RNA from laser-microdissected primary breast tissue with oligonucleotide arrays. , 2005, The Journal of molecular diagnostics : JMD.

[4]  R. Hruban,et al.  Characterization of gene expression in mucinous cystic neoplasms of the pancreas using oligonucleotide microarrays , 2004, Oncogene.

[5]  Patricia Soteropoulos,et al.  Association between gene expression profile and tumor invasion in oral squamous cell carcinoma. , 2004, Cancer genetics and cytogenetics.

[6]  M. Evans,et al.  Cellular repair of oxidatively induced DNA base lesions is defective in prostate cancer cell lines, PC-3 and DU-145. , 2004, Carcinogenesis.

[7]  N. Nemoto,et al.  Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. , 2004, European urology.

[8]  Chuan-Yuan Li,et al.  GW112, A Novel Antiapoptotic Protein That Promotes Tumor Growth , 2004, Cancer Research.

[9]  S. Ekker,et al.  Syndecan-2 is essential for angiogenic sprouting during zebrafish development. , 2004, Blood.

[10]  R. Tibshirani,et al.  Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Zhou Wang,et al.  Gadd45γ is androgen-responsive and growth-inhibitory in prostate cancer cells , 2004, Molecular and Cellular Endocrinology.

[12]  G. R. Stevens,et al.  Androgen ablation therapy for prostate carcinoma suppresses the immunoreactive telomerase subunit hTERT , 2004, Cancer.

[13]  Z. Culig.  Androgen Receptor Cross-talk with Cell Signalling Pathways , 2004, Growth factors.

[14]  E. Latulippe,et al.  Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. , 2004, The American journal of pathology.

[15]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.

[16]  M. Fornaro,et al.  Fibronectin Protects Prostate Cancer Cells from Tumor Necrosis Factor-α-induced Apoptosis via the AKT/Survivin Pathway* , 2003, Journal of Biological Chemistry.

[17]  Hans-Georg Rammensee,et al.  Moderate degradation does not preclude microarray analysis of small amounts of RNA. , 2003, BioTechniques.

[18]  Douglas A. Hosack,et al.  Identifying biological themes within lists of genes with EASE , 2003, Genome Biology.

[19]  F. Bethencourt,et al.  Pro-apoptotic tumor necrosis factor-alpha transduction pathway in normal prostate, benign prostatic hyperplasia and prostatic carcinoma. , 2003, The Journal of urology.

[20]  J. Cheville,et al.  Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. , 2003, Cancer research.

[21]  Yingdong Zhao,et al.  Molecular Differentiation of High- and Moderate-Grade Human Prostate Cancer by cDNA Microarray Analysis , 2003, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[22]  H. Ito,et al.  Androgen receptor involvement in the progression of prostate cancer. , 2003, Endocrine-related cancer.

[23]  S. Parodi,et al.  Nuclear matrix proteins changes in cancerous prostate tissues and their prognostic value in clinically localized prostate cancer , 2003, The Prostate.

[24]  T. Libermann,et al.  Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. , 2003, Cancer research.

[25]  A. Scherer,et al.  Optimized protocol for linear RNA amplification and application to gene expression profiling of human renal biopsies. , 2003, BioTechniques.

[26]  Karl Kornacker,et al.  Chipping away at the chip bias: RNA degradation in microarray analysis , 2003, Nature Genetics.

[27]  J. Warrington,et al.  Accurate and reproducible gene expression profiles from laser capture microdissection, transcript amplification, and high density oligonucleotide microarray analysis. , 2003, The Journal of molecular diagnostics : JMD.

[28]  R. Montironi,et al.  Elevated E-Cadherin and α/β-Catenin Expression after Androgen Deprivation Therapy in Prostate Adenocarcinoma , 2003 .

[29]  E. Lander,et al.  A molecular signature of metastasis in primary solid tumors , 2003, Nature Genetics.

[30]  T. Hastie,et al.  Optimization and evaluation of T7 based RNA linear amplification protocols for cDNA microarray analysis , 2002, BMC Genomics.

[31]  E. Latulippe,et al.  Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. , 2002, Cancer research.

[32]  Franklin Peale,et al.  In silico data filtering to identify new angiogenesis targets from a large in vitro gene profiling data set. , 2002, Physiological genomics.

[33]  E. Lander,et al.  Gene expression correlates of clinical prostate cancer behavior. , 2002, Cancer cell.

[34]  T. Rabbitts,et al.  The LIM-domain protein Lmo2 is a key regulator of tumour angiogenesis: a new anti-angiogenesis drug target , 2002, Oncogene.

[35]  M. Hendrix,et al.  Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: Role in vasculogenic mimicry , 2002, The Prostate.

[36]  Gallya Gannot,et al.  Evaluation of non-formalin tissue fixation for molecular profiling studies. , 2002, The American journal of pathology.

[37]  Rajiv Dhir,et al.  Gene expression analysis of prostate cancers , 2002, Molecular carcinogenesis.

[38]  T. Visakorpi,et al.  Molecular genetics of prostate cancer. , 2003, Annals of medicine.

[39]  S. Parsons,et al.  Interleukin-6- and Cyclic AMP-Mediated Signaling Potentiates Neuroendocrine Differentiation of LNCaP Prostate Tumor Cells , 2001, Molecular and Cellular Biology.

[40]  D. Feldman,et al.  The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.

[41]  S. Dhanasekaran,et al.  Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.

[42]  J. Welsh,et al.  Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. , 2001, Cancer research.

[43]  R. Ball,et al.  Differential expression of the ccn3 (nov) proto-oncogene in human prostate cell lines and tissues , 2001, Molecular pathology : MP.

[44]  G. Mills,et al.  Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. , 2001, Journal of the National Cancer Institute.

[45]  John Calvin Reed,et al.  MEK/ERK signaling pathway regulates the expression of Bcl‐2, Bcl‐XL, and Mcl‐1 and promotes survival of human pancreatic cancer cells , 2000, Journal of cellular biochemistry.

[46]  C. Kwak,et al.  The application of an antiangiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts , 2000, Cancer Gene Therapy.

[47]  R. Weigel,et al.  PDZK1 and GREB1 are estrogen-regulated genes expressed in hormone-responsive breast cancer. , 2000, Cancer research.

[48]  Lukasz Huminiecki,et al.  In Silico Cloning of Novel Endothelial-Specific Genes , 2000 .

[49]  M. Cintorino,et al.  Macrophage migration inhibitory factor in prostatic adenocarcinoma: Correlation with tumor grading and combination endocrine treatment‐related changes , 2000, The Prostate.

[50]  D. Bostwick,et al.  Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer , 2000, Cancer.

[51]  L. Murphy,et al.  Expression of a repressor of estrogen receptor activity in human breast tumors: relationship to some known prognostic markers. , 2000, Cancer research.

[52]  C. Pilarsky,et al.  Differential gene expression by endothelial cells in distinct angiogenic states. , 2000, European journal of biochemistry.

[53]  J. Schalken,et al.  Cadherin switching in human prostate cancer progression. , 2000, Cancer research.

[54]  Bostwick Dg.  Immunohistochemical changes in prostate cancer after androgen deprivation therapy. , 2000 .

[55]  D. Bostwick.  Immunohistochemical changes in prostate cancer after androgen deprivation therapy. , 2000, Molecular urology.

[56]  R. Bataille,et al.  IL‐6 up‐regulates Mcl‐1 in human myeloma cells through JAK / STAT rather than Ras / MAP kinase pathway , 1999, European journal of immunology.

[57]  N. Bruchovsky,et al.  Prostate cancer: molecular biology of early progression to androgen independence. , 1999, Endocrine-related cancer.

[58]  S. Wahl,et al.  Apoptosis induction by a novel anti-prostate cancer compound, BMD188 (a fatty acid-containing hydroxamic acid), requires the mitochondrial respiratory chain. , 1999, Cancer research.

[59]  L. Liotta,et al.  Chromosome 16 allelic loss analysis of a large set of microdissected prostate carcinomas. , 1999, The Journal of urology.

[60]  M. Birch,et al.  Differential regulation of syndecan expression by osteosarcoma cell lines in response to cytokines but not osteotropic hormones. , 1999, Bone.

[61]  O. Lukkarinen,et al.  Three independently deleted regions at chromosome arm 16q in human prostate cancer: allelic loss at 16q24.1–q24.2 is associated with aggressive behaviour of the disease, recurrent growth, poor differentiation of the tumour and poor prognosis for the patient , 1999, British journal of cancer.

[62]  G. Ciliberto,et al.  Blocking signaling through the gp130 receptor chain by interleukin‐6 and oncostatin M inhibits PC‐3 cell growth and sensitizes the tumor cells to etoposide and cisplatin‐mediated cytotoxicity , 1999, Cancer.

[63]  H. Klocker,et al.  Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. , 1998, Cancer research.

[64]  J. Overgaard,et al.  Immunohistochemical determination of tumor angiogenesis measured by the maximal microvessel density in human prostate cancer , 1998, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[65]  T. Visakorpi,et al.  Increased cell proliferation activity and decreased cell death are associated with the emergence of hormone‐refractory recurrent prostate cancer , 1997, The Journal of pathology.

[66]  John Calvin Reed,et al.  Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. , 1996, The American journal of pathology.

[67]  N. L. Johnson,et al.  Multivariate Analysis , 1958, Nature.